Researchers published complementary platforms that expand control over RNA sequences by harnessing single‑strand deaminases. Two papers in Nature Biotechnology describe methods that simultaneously rewrite multiple bases within single transcripts and an adjustable deaminase system that improves site selectivity. Both teams reported robust editing in cellular models and highlighted delivery and specificity as the next translational hurdles. The work demonstrates transient, programmable RNA edits rather than permanent DNA changes—an approach that can modulate gene expression or protein function without altering the genome. Authors detailed on‑target efficiencies and initial off‑target profiles, and noted potential applications in treating disorders driven by aberrant RNA or for temporary therapeutic modulation. Clinical translation will depend on vehicle development and further safety profiling; the studies position RNA editing as a flexible complement to DNA‑based gene therapies for indications where reversibility and dosing control matter.